Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc.
Bullboard Posts
User Avatar Image
(1)
•••
Post by skyhigh123on Mar 12, 2018 7:55am
284 Views
Post# 27699236

FDA LIST (April 2 companies have already been Approved)

FDA LIST (April 2 companies have already been Approved)
CLVS CLOVIS ONCOLOGY PDUFA
WhenFriday, Apr 6, 2018
Description2018-04-06 BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) has accepted the companys supplemental New Drug Application (sNDA) for rucaparib and granted priority review status to the application with a Prescription Drug User Fee Act (PDUFA) date of April 6, 2018. https://www.businesswire.com/news/home/20171205006349/en/Clovis-Announces-Priority-Review-Designation-Rucaparib-Supplemental
more details»  copy to my calendar
 PCRX Pacira Pharmaceuticals, Inc. PDUFA
WhenFriday, Apr 6, 2018
Description2018-04-06 The expected action date by the FDA under the Prescription Drug User Fee Act (PDUFA) is April 6, 2018. https://www.globenewswire.com/news-release/2017/10/18/1149139/0/en/Pacira-Pharmaceuticals-Announces-FDA-Acceptance-of-sNDA-for-EXPAREL-as-a-Nerve-Block-to-Produce-Regional-Analgesia.html
more details»  copy to my calendar
Saturday, April 14
 PFSCF ProMetic Life Sciences Inc. PDUFA
WhenSaturday, Apr 14, 2018
Description2018-04-14 Prescription Drug User Fee Act (PDUFA) action date is set for April 14, 2018 https://www.prnewswire.com/news-releases/prometic-announces-fda-acceptance-of-its-biologics-license-application-for-plasminogen-ryplazim-650738623.html
more details»  copy to my calendar

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities